Clinical Trial Update: Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) [Phase 3]

View source ↗

Summary

Phase 3 extension study evaluating the efficacy and safety of ianalumab in lupus nephritis, with or without withdrawal of other study treatment, currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• Ianalumab (ianalumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Lupus Nephritis | Phase 3 | Status: RECRUITING